NASDAQ · PHARMACEUTICAL PREPARATIONS · MID CAP
Adagene Inc. ADAG
8 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 7.7M
Revenue, FY2025 · full 8-year series below
Revenue $M
Net income $M
FY2025 · Revenue 7.7 · Net income -17.6
Compound annual growth
Revenue compounded at +61.4% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−230 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -279.5% · Net -229.6%
ROE
FY2025 · ROE -41.0%
Each USD of equity lost 41 cents this year.
The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Income tax $B | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | · | · | · |
| Net income $B | −0.0 | −0.0 | −0.0 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −0.30 | −0.59 | −0.35 | −1.48 | −1.46 | −2.67 | −1.10 | −0.94 |
| Dividend / sh $ | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · |
| ROE % | −41.0 | −55.2 | −24.7 | −66.7 | −217.9 | · | · | · |
| Shares out B | 0.06 | 0.06 | 0.06 | 0.05 | 0.05 | 0.02 | 0.02 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 30 reconciliationsAUDITED
Reconciled in 8 of 19 fiscal years. 46 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code E9
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2018